hotspot -WSS

hotspot

author：entertainment 2025-08-11 02:12:27 - browse：4595

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： CDC picks Alphabet's Verily for wasterwater surveillance contract

focus

leisure time

WSS

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

CRISPR base editing slashes cholesterol levels in monkeys

STAT Readout Newsletter: Biotech news today

STAT Summit: Meghan O’Rourke on making chronic illness visible

Setback for rare diseases as Taysha Gene Therapies pulls back

Some top drug companies are starting to take action on climate

hotspot

hotspot

focus

Virginia high school admissions case could be legal follow

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Novavax promises a turnaround & Lilly roils the obesity market

CDC picks Alphabet's Verily for wasterwater surveillance contract

What does generative AI mean for health care? We asked experts

Health tech investors get more selective as pandemic boom fades

Moonlake's readout produced a cash windfall. Risks remain

Results on Novartis prostate cancer therapy could expand its use

Psychedelics group wrestles with new pharma identity

What will Novo Nordisk's VC do with its influx of cash?

knowledge

Stop Congress from blocking public access to science

STAT Readout Newsletter: Biotech news today

STAT Readout Newsletter: Biotech news today

Why a market frenzy over new weight loss drugs defies logic

STAT Summit: How researchers deal with rejection

ADCs take center stage as promising cancer treatments

leisure time

focus

leisure time

entertainment